Atlas Trials

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

Clinical trial NCT02109224 · TERMINATED

Trial details

NCT number
NCT02109224
Sponsor
National Cancer Institute (NCI)
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Adult B Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaCutaneous B-Cell Non-Hodgkin LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueHIV InfectionIntraocular LymphomaMulticentric Angiofollicular Lymphoid HyperplasiaNodal Marginal Zone LymphomaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell Lymphoma
Start date
2014-09-01
Primary completion
2015-07-01
Enrollment
72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.